Detalhe da pesquisa
1.
Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
Liver Int
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618972
2.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313048
3.
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Oncologist
; 25(8): e1181-e1187, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311799
4.
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
BMC Cancer
; 19(1): 433, 2019 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31077164
5.
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
Liver Cancer
; 13(1): 89-98, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344445
6.
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
JHEP Rep
; 5(4): 100672, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866388
7.
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.
Liver Cancer
; 12(6): 510-520, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38058419
8.
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
Clin Cancer Res
; 28(16): 3537-3545, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435967
9.
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Cancers (Basel)
; 14(23)2022 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497316
10.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Eur J Cancer
; 175: 204-213, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36148739
11.
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
Liver Cancer
; 10(3): 240-248, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239810